论文部分内容阅读
近10余年来对急性淋巴细胞白血病(ALL)的治疗已取得了巨大的成绩。在国外,儿童ALL 的5年完全缓解率已达65～70%,预计其中85%的患儿可治愈。但少数病人始终不能缓解,而已缓解的病人也可能很快复发。近来对 ALL 的研究,特别是在免疫学分型、染色体、治疗及远期预后等方面的研究,又取得了一些新的进展。ALL 的免疫学分型ALL 是一种“杂源性”疾病。不少学者从免疫学角度,利用细胞表面标志与血清学方法将、ALL 分为多个亚型,这是70年代 ALL研究的重要进展之一。ALL 大多数属非 T 非
Nearly 10 years of treatment of acute lymphoblastic leukemia (ALL) has made great achievements. Abroad, the 5-year complete remission rate of children ALL has reached 65 to 70%, 85% of them are expected to be curable. However, a small number of patients can not always alleviate, and patients who have been alleviated may also relapse soon. Recent research on ALL, especially in immunological typing, chromosomes, treatment and long-term prognosis, made some new progress. ALL’s immunological typing ALL is a “heterozygous” disease. Many scholars from the immunological point of view, the use of cell surface markers and serological methods, ALL divided into multiple subtypes, which is one of the important research progress 70 years ALL. Most of the non-T ALL non-T non